Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LC542019 in Healthy Subjects and Subjects With T2DM
NCT06333977Phase 1Completed
- Sponsor
- LG Chem
- Start
- Mar 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LC542019 in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by LG Chem. Primary endpoint: Incidence, severity of adverse events up to 4 weeks. Started Mar 2022; status: completed.
02
Drugs
LC542019
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06333977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06333977.